The reiteration of a Neutral rating and maintenance of a $21 price target by Wedbush suggests a stable outlook for Regenxbio's stock in the short term. The analyst's perspective indicates no significant changes expected in the company's valuation or market performance, leading to a neutral impact on the stock price.